• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性和散发性 2 型乳头状肾细胞癌之间存在抗氧化反应表型。

An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.

机构信息

Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA.

出版信息

Cancer Cell. 2011 Oct 18;20(4):511-23. doi: 10.1016/j.ccr.2011.08.024.

DOI:10.1016/j.ccr.2011.08.024
PMID:22014576
Abstract

Fumarate hydratase (FH) mutation causes hereditary type 2 papillary renal cell carcinoma (PRCC2). The main effect of FH mutation is fumarate accumulation. The current paradigm posits that the main consequence of fumarate accumulation is HIF-α stabilization. Paradoxically, FH mutation differs from other HIF-α stabilizing mutations, such as VHL and SDH mutations, in its associated tumor types. We identified that fumarate can directly up-regulate antioxidant response element (ARE)-controlled genes. We demonstrated that aldo-keto reductase family 1 member B10 (AKR1B10) is an ARE-controlled gene and is up-regulated upon FH knockdown as well as in FH null cell lines. AKR1B10 overexpression is also a prominent feature in both hereditary and sporadic PRCC2. This phenotype better explains the similarities between hereditary and sporadic PRCC2.

摘要

延胡索酸水合酶(FH)突变导致遗传性 2 型乳头状肾细胞癌(PRCC2)。FH 突变的主要作用是积累富马酸。目前的范式假设,富马酸积累的主要后果是 HIF-α 稳定。矛盾的是,FH 突变与其相关的肿瘤类型不同于其他 HIF-α 稳定突变,如 VHL 和 SDH 突变。我们发现富马酸可以直接上调抗氧化反应元件(ARE)控制的基因。我们证明醛酮还原酶家族 1 成员 B10(AKR1B10)是一个 ARE 控制的基因,并在 FH 敲低以及 FH 缺失细胞系中上调。AKR1B10 的过表达也是遗传性和散发性 PRCC2 的一个显著特征。这种表型更好地解释了遗传性和散发性 PRCC2 之间的相似性。

相似文献

1
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.遗传性和散发性 2 型乳头状肾细胞癌之间存在抗氧化反应表型。
Cancer Cell. 2011 Oct 18;20(4):511-23. doi: 10.1016/j.ccr.2011.08.024.
2
CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.CUL3 和 NRF2 突变赋予散发性乳头状肾细胞癌中的 NRF2 激活表型。
Cancer Res. 2013 Apr 1;73(7):2044-51. doi: 10.1158/0008-5472.CAN-12-3227. Epub 2013 Jan 30.
3
Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and "cryptic targets" of transcription factors.肾肿瘤中富马酸水合酶失活:缺氧诱导因子1α、核因子E2相关因子2及转录因子的“隐匿靶点”
Chin J Cancer. 2012 Sep;31(9):413-20. doi: 10.5732/cjc.012.10102. Epub 2012 Jul 2.
4
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.缺氧诱导因子(HIF)过表达与肾癌中富马酸水合酶的双等位基因缺失相关:富马酸在调节HIF稳定性中的新作用。
Cancer Cell. 2005 Aug;8(2):143-53. doi: 10.1016/j.ccr.2005.06.017.
5
Novel insights into FH-associated disease are KEAPing the lid on oncogenic HIF signalling.对家族性高胆固醇血症相关疾病的新见解正在抑制致癌性缺氧诱导因子信号通路。 (注:KEAP可能是keep a lid on的错误表述,根据语境推测是“抑制”的意思,原句中KEAPing应改为Keeping)
Oncotarget. 2011 Nov;2(11):820-1. doi: 10.18632/oncotarget.348.
6
Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2.富马酸水合酶缺陷细胞系NCCFH1作为2型遗传性乳头状肾细胞癌的新型体外模型
Anticancer Res. 2015 Dec;35(12):6639-53.
7
Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.琥珀酸脱氢酶在肾透明细胞癌中的低表达介导 HIF-2α 的积累,并促进迁移和侵袭。
PLoS One. 2011;6(6):e21037. doi: 10.1371/journal.pone.0021037. Epub 2011 Jun 14.
8
Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability.琥珀酸脱氢酶(SDH)和延胡索酸水合酶(FH)缺陷型肿瘤中缺氧诱导因子1α(HIF1α)的增加不会导致微卫星不稳定。
Int J Cancer. 2007 Sep 15;121(6):1386-9. doi: 10.1002/ijc.22819.
9
Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.延胡索酸水合酶缺陷进行性阶段的表达谱:代谢变化对肿瘤发生的贡献。
Cancer Res. 2010 Nov 15;70(22):9153-65. doi: 10.1158/0008-5472.CAN-10-1949. Epub 2010 Oct 26.
10
Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes.肾髓质癌:与多种基因型相关的组织病理学表型。
Hum Pathol. 2011 Dec;42(12):1979-88. doi: 10.1016/j.humpath.2011.02.026. Epub 2011 Jul 5.

引用本文的文献

1
NRF2 activation in cancer and overview of NRF2 small molecule inhibitors.癌症中的NRF2激活及NRF2小分子抑制剂概述。
Arch Pharm Res. 2025 Aug 15. doi: 10.1007/s12272-025-01557-x.
2
Oxygen needs sulfur, sulfur needs oxygen: a relationship of interdependence.氧需要硫,硫需要氧:一种相互依存的关系。
EMBO J. 2025 May 20. doi: 10.1038/s44318-025-00464-7.
3
Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.健康立场文件与氧化还原观点——非传染性疾病中NRF2药理调节从 bench 到床边的转化
Redox Biol. 2025 Apr;81:103569. doi: 10.1016/j.redox.2025.103569. Epub 2025 Mar 3.
4
Thirty years of NRF2: advances and therapeutic challenges.NRF2的三十年:进展与治疗挑战
Nat Rev Drug Discov. 2025 Mar 4. doi: 10.1038/s41573-025-01145-0.
5
Oxidative stress and NRF2 signaling in kidney injury.肾脏损伤中的氧化应激与NRF2信号传导
Toxicol Res. 2024 Dec 22;41(2):131-147. doi: 10.1007/s43188-024-00272-x. eCollection 2025 Mar.
6
Selective inhibition of TGF-β-induced epithelial-mesenchymal transition overcomes chemotherapy resistance in high-risk lung squamous cell carcinoma.选择性抑制转化生长因子-β诱导的上皮-间质转化可克服高危肺鳞状细胞癌的化疗耐药性。
Commun Biol. 2025 Feb 1;8(1):152. doi: 10.1038/s42003-025-07595-x.
7
Nrf2 Signaling in Renal Cell Carcinoma: A Potential Candidate for the Development of Novel Therapeutic Strategies.肾细胞癌中的Nrf2信号通路:新型治疗策略开发的潜在候选对象
Int J Mol Sci. 2024 Dec 10;25(24):13239. doi: 10.3390/ijms252413239.
8
The pan-cancer landscape of aldo-keto reductase1B10 reveals that its expression is diminished in gastric cancer.醛酮还原酶1B10的泛癌图谱显示,其在胃癌中的表达降低。
Front Immunol. 2024 Dec 6;15:1488042. doi: 10.3389/fimmu.2024.1488042. eCollection 2024.
9
Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma.利用NRF2-ARE通路激活治疗乳头状肾细胞癌。
Int J Cancer. 2025 Apr 1;156(7):1457-1469. doi: 10.1002/ijc.35311. Epub 2024 Dec 20.
10
Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer.癌症中处于遗传、表观遗传和生态改变交叉点的肿瘤代谢物。
Cell Death Differ. 2024 Dec;31(12):1582-1594. doi: 10.1038/s41418-024-01402-6. Epub 2024 Oct 23.